详细信息
中药新药研发中证候规范化及其临床疗效评价 被引量:12
Syndrome Standardization and Clinical Efficacy Evaluation in Research and Development of New Patent Chinese Medicine
文献类型:期刊文献
中文题名:中药新药研发中证候规范化及其临床疗效评价
英文题名:Syndrome Standardization and Clinical Efficacy Evaluation in Research and Development of New Patent Chinese Medicine
作者:朱立鸣[1];卢健[2];段永强[1]
第一作者:朱立鸣
机构:[1]甘肃中医学院,甘肃兰州730000;[2]咸阳市中心医院,陕西咸阳712000
第一机构:甘肃中医药大学
年份:2006
卷号:12
期号:7
起止页码:533
中文期刊名:中国中医基础医学杂志
外文期刊名:JOURNAL OF BASIC CHINESE MEDICINE
收录:CSTPCD;;北大核心:【北大核心2004】;CSCD:【CSCD_E2011_2012】;
语种:中文
中文关键词:中药;新药;证候;规范化
外文关键词:Chinese crude drug/New drug ; Syndrome-penthemeron ; Normalization
摘要:证候规范化在中药新药研发中具有重要的地位,是筛选中药组方、确立功效范围、指导临床运用的主要依据。证候的规范化可以通过借鉴古籍记载、临床经验等来源,经过量化和客观化分析,确立公认的、临床实际可操作性的具体指标,以建立证候的临床诊断标准而便于客观评价。
Normalization of syndrome-penthemeron has a very important position in sieving Chinese crude drug,establishing effectiveness and instructing clinical apply. Concrete indicatrix of normalization of received and practical syndrome-penthemeron was established by records of ancient books and clinical experiences. So this kind of standard of clinical diagnosis is good to objective evaluation.
参考文献:
正在载入数据...